BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer & Founder
Rob Risinger - Chief Medical Officer, Neuroscience
Matt Wiley - Chief Commercial Officer
Richard Steinhart - Chief Financial Officer
Conference Call Participants
Robyn Karnauskas - Truist Securities
Mary Kate - Bank of America
Colin Bristow - UBS
Yatin Suneja - Guggenheim Partners
Sumant Kulkarni - Canaccord Genuity
Ram Selvaraju - H.C. Wainwright
Operator
Good morning, and welcome to the BioXcel Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's annual report on Form 10-K for the year ended December 31, 2022, which can be found at www.bioxceltherapeutics.com or on www.sec.gov and which will be updated in its quarterly report on Form 10-Q for the quarter ended March 31, 2023. As a reminder, today's conference is being recorded.
Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Vince O'Neill, Chief R&D Officer of OnkosXcel Therapeutics; and Dr. Frank Yocca, Chief Scientific Officer. It is now my pleasure to turn the call over to Dr. Mehta, the CEO and Founder of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome, everyone, and thank you for joining our call today to discuss BioXcel Therapeutics' first quarter 2023 financial performance and business highlights. This is shaping up to be a momentous year for BioXcel Therapeutics. Our success in advancing our corporate objectives continues on an exciting trajectory.
We are maturing as a commercial organization, solidifying our position as a leading innovator in a nascent agitation market and advancing our pipeline towards critical value-creating and business transformative milestones. We believe we are well on track to realizing our vision of becoming the leading AI-enabled neuroscience company. I have truly never been more excited than I am today for BioXcel's promising future.